Interleukin-2 levels in chronic schizophrenia patients

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 3, 2004, Pages 320-323

  Mahendran, Rathi ^a   Mahendran, R ^b   Chan, Y H ^c  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c National Medical Research Council   (Singapore)

Author keywords

Cytokines; Psychopathology

Indexed keywords

CHLORPROMAZINE; INTERLEUKIN 2; NEUROLEPTIC AGENT; PHYTOHEMAGGLUTININ;

ADULT; AGE; AGED; ARTICLE; ASIAN; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CHINESE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; HUMAN; INDIAN; MALAY; MENTAL DISEASE; NEGATIVE SYNDROME; POSITIVE SYNDROME; SCHIZOPHRENIA;

EID: 3142721344     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. rd ed. Chapter 10. London: Mosby, 1996.
2. Neurobiology of Cytokines. Part A. In: De Souza EB, editor. Methods in Neurosciences. Vol 16. New York: Academic Press, 1993:xiii.
3. Muller N, Ackenheil M. Psychoneuroimmunolgy and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33.
4. Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 1992;44:113-23.
5. Smith RS. Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes? Med Hypotheses 1991;34:225-9.
6. Sirota P, Fishman P, Elizur A, Djaldetty M. Lymphokine production in schizophrenic patients. Biol Psychiatry 1990;27:173A.
7. Rapaport MH, McAllister G, Pickar D, Nelson DL, Paul SM. Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch Gen Psychiatry 1989;46:291-2.
8. Ganguli R, Rabin B S, Belle SH. Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 1989;26:427-30.
9. Villemain F, Chatenoud L, Galinowski A, Homos-Delarche F, Ginestet D, Loo H, et al. Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 1989;146:609-16.
10. Ganguli R, Brar JS, Chengappa KNR, DeLeo M, Yang ZW, Shurin G, et al. Mitogen-stimulated IL-2 production in never-medicated first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 1995;52:668-72.
11. Pollmacher T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A. Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 1997;154:1763-5.
12. Yong K K, Min S L, Kwang Y S. Decreased interleukin-2 production in Korean schizophrenia patients. Biol Psychiatry 1998;43:701-4.
13. Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res 1992;6:181-92.
14. Baldwin JA. Schizophrenia and physical disease: a preliminary analysis of the data from the Oxford record linkage study. In: Hemmings G. editor. Biochemistry of Schizophrenia and Addiction. Lancaster: MTP. 1980:297-318.
15. Finney GOH. Juvenile onset diabetes and schizophrenia? Lancet 1989;ii:1214-5.
16. Sirota P, Schild K, Firer M, Tanay A, Elizur A, Meytes D, et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry 1991;29:103a.
17. Ganguli R, Rabin B S, Kelly R H, Lyte M, Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann N Y Acad Sci 1987;496:676-850.
18. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994;51:1-10.
19. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 1995;38:297-302.
20. Leykin I, Mayer R, Deckmann M, Shinitzky M. Immunosuppressive effect of neuroleptic drugs - is it integrated in their antipsychotic action? Eur Neuropsychopharmacol 1996;6:S4-113